RJA
VYNE icon

Raymond James & Associates’s VYNE Therapeutics VYNE Stock Holding History

Raymond James & Associates’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-768
Closed -$95K – 4225
2021
Q1 		$95K Buy
768
+8
+1% +$1.16K ﹤0.01% 3788
2020
Q4 		$86K Hold
760
– – ﹤0.01% 3579
2020
Q3 		$91K Hold
760
– – ﹤0.01% 3387
2020
Q2 		$95K Buy
760
+490
+181% +$66.4K ﹤0.01% 3295
2020
Q1 		$52K Buy
+270
New +$84.7K ﹤0.01% 3313

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Raymond James & Associates's VYNE Position: Q2 2021 in Review

Raymond James & Associates sold out of VYNE Therapeutics (VYNE) in Q2 2021, closing a stake of 768 shares — an estimated $95K sold.

Raymond James & Associates first reported a position in VYNE in Q1 2020 and held it in 5 quarters. The position peaked at $95K in Q1 2021. 72 funds tracked by Wall St. Rank hold VYNE as of Q2 2021.

  • Raymond James & Associates reported no remaining VYNE Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 768 VYNE Therapeutics shares in Q2 2021, an estimated $95K.
  • Raymond James & Associates first reported a position in VYNE Therapeutics in Q1 2020 and held it in 5 quarters.
  • Raymond James & Associates's VYNE Therapeutics position peaked at $95K in Q1 2021.
  • 72 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.